Paul Francis Olivier te Boekhorst, President and CEO of Immucell Corp, has reported a significant stock transaction involving both common shares and stock options. This filing, made on November 16, 2026, highlights his ongoing investment in the company and may impact shareholder perceptions and management dynamics.

Background

Immucell Corp, incorporated in Delaware, operates in the life sciences sector, specifically focusing on in vitro and in vivo diagnostic substances. The company is listed under the Central Index Key (CIK) number 0000811641. Recent filings show a consistent pattern of ownership changes, reflecting active management engagement.

What the Filing Says

In the recent filing, te Boekhorst reported the acquisition of 16,393 shares of Immucell common stock at a price of $6.10 per share on November 12, 2026. Following this transaction, he holds a total of 34,131 shares. Additionally, he exercised stock options for the same number of shares, which were granted at an exercise price of $6.10. This exercise is part of a broader incentive plan aimed at aligning management interests with those of shareholders.

Impact

This transaction may affect various stakeholders within Immucell Corp, particularly shareholders who may view the CEO's increased ownership as a positive sign of confidence in the company's future. The filing also corrects a previous report, noting a minor adjustment in total ownership from a June 22, 2026, filing.

What's Next

The filing does not say what happens next.